Get the Stockscreener App
19.18
3.67%
-0.73
After Hours:
19.18
Relay Therapeutics Inc stock is traded at $19.18, with a volume of 2.30M.
It is down -3.67% in the last 24 hours and up +20.78% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$19.91
Open:
$19.95
24h Volume:
2.30M
Relative Volume:
0.57
Market Cap:
$4.18B
Revenue:
$10.68M
Net Income/Loss:
$-272.71M
P/E Ratio:
-12.26
EPS:
-1.565
Net Cash Flow:
$-213.38M
1W Performance:
+2.40%
1M Performance:
+20.78%
6M Performance:
+158.84%
1Y Performance:
+448.00%
1-Day Range:
$19.15
$20.39
1-Week Range:
$18.40
$20.39
52-Week Range:
$3.025
$20.79
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
19.18 | 4.34B | 10.68M | -272.71M | -213.38M | -1.565 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 123.26B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.94B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 53.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 39.58B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 35.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Certain Stock Options of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
Certain Common Stock of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
Why Is RLAY Stock Rising Today? - Stocktwits
Relay Therapeutics (RLAY) Edges Higher as Stock Tests Key Resistance at $20.68High Volume Stocks - dars.gov.et
Canaccord initiates Relay Therapeutics stock with buy rating - Investing.com
Canaccord initiates Relay Therapeutics stock with buy rating By Investing.com - Investing.com UK
RLAY Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus
CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29 - Moomoo
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
Relay Therapeutics Inc. (RLAY) Q1 2026 Earnings: EPS Miss Weighs on Shares as Pipeline Progress Waits - Bölüm Sonu Canavarı
Relay Therapeutics president sells $162,028 in company stock - Investing.com UK
Relay Therapeutics Insider Sold Shares Worth $331,131, According to a Recent SEC Filing - Moomoo
Insider Sell Alert: Donald Bergstrom Sells Shares of Relay Thera - GuruFocus
Form 4 Relay Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Relay Therapeutics president and CEO Sanjiv Patel sells $943,736 in stock - Investing.com Nigeria
Relay Therapeutics (RLAY) R&D chief sells 8,660 shares in 10b5-1 trade - Stock Titan
Relay Therapeutics CFO Thomas Catinazzo sells $331,130 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics Insider Sold Shares Worth $943,736, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics president sells $162,028 in company stock By Investing.com - Investing.com UK
Relay Therapeutics (RLAY) CEO trades shares, keeps over 615K direct holdings - Stock Titan
CFO at Relay Therapeutics (RLAY) sells shares under Rule 10b5-1 plan - Stock Titan
Why Relay Therapeutics (RLAY) Is Up 5.5% After Broad Russell Growth Index Inclusion And What's Next - simplywall.st
JPMorgan initiates Relay Therapeutics stock coverage with overweight rating By Investing.com - Investing.com Nigeria
JPMorgan initiates Relay Therapeutics stock coverage with overweight rating - Investing.com
RLAY Initiated Coverage by JP Morgan -- Rating Overweight with T - GuruFocus
Form 144 RELAY THERAPEUTICS INC For: 7 July By Investing.com - Investing.com Nigeria
Relay Therapeutics stock hits 52-week high at 19.97 USD By Investing.com - Investing.com South Africa
Relay Therapeutics stock hits 52-week high at 19.97 USD - Investing.com
Enterprise value to revenue forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
Enterprise value to EBIT forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
Price to sales forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
Price to earnings forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
Relay Therapeutics (RLAY) Gains Modestly as Trading Volume Picks UpNAAIM Exposure - dars.gov.et
Price to book forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
RLAYRelay Therapeutics Inc Latest SEC Filings - Finviz
Insider Sell: Peter Rahmer Sells 50,000 Shares of Relay Therapeu - GuruFocus
Relay Therapeutics (RLAY) exec ESPP buy, 50K-share 10b5-1 sale - Stock Titan
Relay Therapeutics (RLAY) Joins Multiple Russell Growth Indexes Is Its Biotech Role Being Repriced? - simplywall.st
Form 144 RELAY THERAPEUTICS INC For: 30 June By Investing.com - Investing.com South Africa
RLAY (NASDAQ: RLAY) Form 144: 50,000 Performance Stock Units; 753-share sale - Stock Titan
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year - Yahoo Finance
RLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisib - MSN
Relay Therapeutics, Inc.(NasdaqGM:RLAY) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Relay Therapeutics, Inc.(NasdaqGM: RLAY) added to Russell 2500 Growth Benchmark - marketscreener.com
Relay Therapeutics, Inc.(NasdaqGM: RLAY) added to Russell 2000 Growth Benchmark - marketscreener.com
Relay Therapeutics, Inc.(NasdaqGM: RLAY) added to Russell 3000E Growth Benchmark - marketscreener.com
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
3.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):